Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) announced their participation in two investor conferences, with the CEO and CMO presenting at Guggenheim 6th Annual Biotechnology Conference and TD Cowen 44th Annual Health Care Conference respectively. The webcasts will be available on the company's website.

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

• Guggenheim 6th Annual Biotechnology Conference (New York, NY) – Markus Warmuth, M.D., Chief Executive Officer, to participate in fireside chat, February 7, 2024, at 1:30 p.m. ET.
• TD Cowen 44th Annual Health Care Conference (Boston, MA) – Filip Janku, M.D., Ph.D., Chief Medical Officer, to participate in corporate panel discussion, “Breast and Lung Cancer,” March 6, 2024, at 9:10 a.m. ET.

A webcast of each presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk, Monte Rosa Therapeutics
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

When is Markus Warmuth participating in the fireside chat?

Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, at 1:30 p.m. ET.

Who is participating in the corporate panel discussion at the TD Cowen 44th Annual Health Care Conference?

Filip Janku, M.D., Ph.D., Chief Medical Officer, will participate in the corporate panel discussion on 'Breast and Lung Cancer' at the TD Cowen 44th Annual Health Care Conference on March 6, 2024, at 9:10 a.m. ET.

Where can the webcasts of the presentations be accessed?

The webcasts will be accessible via the 'Events & Presentations' section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.